2024-09-18 - Analysis Report
## REGN Stock Analysis: 

**Company Overview:**  Regeneron Pharmaceuticals, Inc. (REGN) is a leading biotechnology company focused on developing life-transforming medicines for serious diseases.

**1. Performance Analysis:**

* **Cumulative Return:** REGN has generated a cumulative return of 149.55%, significantly outperforming the S&P 500 (VOO) with a cumulative return of 88.56%. 
* **Performance vs. S&P 500:** REGN's performance is currently 60.99% higher than the S&P 500, placing it at the 87.86 percentile of its historical performance against the S&P 500.

**2. Recent Price Action:**

* **Closing Price:** $1139.52
* **5-day Moving Average:** $1150.37
* **20-day Moving Average:** $1169.58
* **60-day Moving Average:** $1113.09
* **Analysis:** The stock price is currently below its 5-day, 20-day, and 60-day moving averages, suggesting a potential downward trend.

**3. Technical Indicators:**

* **RSI:** 32.48 (below 50), indicating a potentially oversold condition.
* **PPO:** -0.57 (negative), suggesting a potential bearish trend.
* **Delta_Previous_Relative_Divergence:** -12.14 (negative), highlighting a recent decline in relative divergence.
* **Expected Return:** 9.18%, indicating a potential 5-year return based on current investment levels.

**4. Recent Earnings and Outlook:**

| Date        | EPS  | Revenue    |
|--------------|------|-------------|
| 2024-08-01 | 13.25| 3.55 B$     |
| 2024-05-02 | 6.7  | 3.15 B$     |
| 2023-11-02 | 9.48 | 3.36 B$     |
| 2023-08-03 | 9.05 | 3.16 B$     |
| 2024-08-01 | 9.05 | 3.16 B$     |

**Analysis:** The most recent earnings report for Q2 2024 showed EPS of 13.25, exceeding analysts' expectations. Revenue also surpassed estimates, reaching 3.55 B$. This positive performance indicates strong growth and reinforces the company's robust financial position.

**5. Overall Analysis:**

REGN has consistently outperformed the market in the past, demonstrating its long-term potential. The recent price decline suggests a potential short-term bearish trend, possibly driven by technical indicators and the potential for short-term market volatility. However, the strong latest earnings report and positive growth outlook suggest that REGN's long-term trajectory remains positive. 

**6. Conclusion:**

While the current price action might indicate a potential short-term pullback, REGN remains a solid long-term investment based on its robust financial performance, strong earnings, and consistent outperformance relative to the market.  Investors should monitor the stock's price action and technical indicators closely to gauge potential entry or exit points. 
